Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis
The Journal of Rheumatology, 08/03/2012
LeBlanc CMA et al. – Canadian children with juvenile idiopathic arthritis may not receive optimal internationally recognized “standard” care because pediatric coverage for biologic drugs through provincial formularies is limited and inconsistent across the country.



